KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Inovio Pharmaceuticals (INO) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Inovio Pharmaceuticals (INO) over the last 17 years, with Q1 2025 value amounting to 38336.97%.

  • Inovio Pharmaceuticals' EBIT Margin changed N/A to 38336.97% in Q1 2025 from the same period last year, while for Sep 2025 it was 49202.88%, marking a year-over-year increase of 95067900.0%. This contributed to the annual value of 51616.91% for FY2024, which is 343166400.0% down from last year.
  • Inovio Pharmaceuticals' EBIT Margin amounted to 38336.97% in Q1 2025.
  • Inovio Pharmaceuticals' 5-year EBIT Margin high stood at 390.61% for Q3 2022, and its period low was 44876.83% during Q4 2022.
  • Over the past 5 years, Inovio Pharmaceuticals' median EBIT Margin value was 20553.16% (recorded in 2021), while the average stood at 23434.95%.
  • The largest annual percentage gain for Inovio Pharmaceuticals' EBIT Margin in the last 5 years was 201625500bps (2022), contrasted with its biggest fall of -323030700bps (2022).
  • Over the past 5 years, Inovio Pharmaceuticals' EBIT Margin (Quarter) stood at 12573.76% in 2021, then tumbled by -257bps to 44876.83% in 2022, then surged by 41bps to 26686.29% in 2023, then soared by 35bps to 17410.77% in 2024, then tumbled by -120bps to 38336.97% in 2025.
  • Its last three reported values are 38336.97% in Q1 2025, 17410.77% for Q4 2024, and 32945.87% during Q2 2024.